Malignant Melanoma
Conditions
Keywords
metastatic melanoma, multiple dose
Brief summary
The purpose of this study is to assess the efficacy, safety, and tolerability of monoclonal antibody therapy using 2 regimens for the treatment of advanced melanoma
Interventions
DRUGCP-675,206
pts treated at 10 mg/kg dose level on a monthly regimen
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed: Stage III (AJCC 6th edition)xxl unresectable melanoma, with measurable disease (either locally relapsed unresectable, in-transit lesions or unresectable draining nodes) or Stage IV melanoma, including: * Metastasis to skin, subcutaneous tissues or distant lymph nodes, or * Metastasis to lungs, or * Metastasis to all other visceral sites with either LDH \<= ULN (upper limit of normal) or a single site of metastasis * Note: Patients with melanoma of ocular origin will be considered ineligible * Documented progressive disease following adjuvant therapy, localized therapy or other therapy for metastatic disease * Measurable disease defined by at least one target lesion that can be accurately measured and whose size is at least 1.0 cm (by spiral CT) or 2.0 cm (by conventional techniques) in its longest diameter * ECOG performance status of 0 or 1 Life expectancy of \> 3 months * Either gender, aged 18 years and above * Adequate bone marrow, hepatic, and renal functions determined within 2 weeks prior to starting therapy, defined as: * Absolute neutrophil count \>= 1.5 x 10(9)cells/L * Platelets \>= 100 x 10(9)/L * Hemoglobin \>= 10 g/dL * Aspartate and alanine aminotransferases (AST, ALT) \<= 2.5 x ULN (\<= 5 x ULN, if documented liver metastases are present) * Total bilirubin \<= 1.5 x ULN * Creatinine \<= 1.5 x ULN * Patients must have recovered from all prior treatment related toxicities, to baseline status, or a CTC grade of 0 or 1. Post-surgical pain shall not be considered a basis for exclusion. * Females must either be not of childbearing potential \[surgically sterilized, which includes tubal ligation, or at least 2 years postmenopausal; not breastfeeding\], or practicing 1 form of approved contraception for at least three months prior to entry into the study with 1 of the following methods: (a) oral contraceptives, (b) intrauterine device, (c) implanted contraceptive (such as Norplant®), (d) injected contraceptives (such as Depo-Provera®), (e) diaphragm, (f) sexual partner must use condom or be surgically sterilized, or (g) sexually inactive. Females of childbearing potential must be instructed to avoid pregnancy during study participation. Negative serum or urine pregnancy test must be documented during screening evaluation. * Must be willing and able to provide written informed consent.
Exclusion criteria
* Received immunotherapy for cancer within one month prior to the start of screening * Patients previously treated on this protocol * History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (e.g. Addison's disease, asthma, celiac disease, multiple sclerosis, Graves Disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc.) * Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history. * History of autoimmune colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin. * Pregnant or lactating women. * Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol. * Diagnosed or suspected brain metastases. Patients with past history of brain metastases but with no radiologic evidence within 12 weeks prior to enter into the protocol will be eligible. * Any serious uncontrolled medical disorder or active infection, which would impair their ability to receive study treatment. * Coexisting malignancies except for basal or squamous cell carcinoma of the skin. * Received any prior CTLA4 inhibiting agent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | At every scheduled visit for a maximum of 2 years from first dose of study drug |
| Tumor response | Assessed every 2-3 months up to 2 years from first dose of study drug |
Secondary
| Measure | Time frame |
|---|---|
| Monitor for human anti-human antibodies at the end of the study | Pre-dose (Cycle 1 only) and end of study |
| Explore genetic influences on safety and or immune response | Pre-dose, Cycle 1 |
| Assess PK during treatment | All cycles as pre-specified in protocol |
Countries
United States
Outcome results
None listed